STOCKHOLM, Oct. 28, 2021 /PRNewswire/ -- Medivir AB
(Nasdaq Stockholm: MVIR) today announces that the nomination
committee now has been appointed ahead of the Annual General
Meeting in May 2022.
According to an AGM resolution, the Nomination Committee 2021-2022
should consist of representatives of at least the three largest
shareholders at the end of the third quarter of 2021 and the
Chairman of the Board.
Work on composing the Nomination Committee is now completed, and
this year's Nomination Committee consists of:
Karl Tobieson (Chairman), appointed by Linc AB
Jan Särlvik, appointed by Nordea
Fonder
Anders Hallberg, appointed by
HealthInvest Partners
Uli Hacksell, Chairman of the Board, Medivir AB
The Annual General Meeting of Medivir will be held on
Thursday May 5, 2022.
For further information, please contact:
Magnus Christensen, interim CEO and
CFO
Phone: +46 (0)8 5468 3100
E-mail: magnus.christensen@medivir.com
About Medivir
Medivir develops innovative drugs with a focus on cancer where
the unmet medical needs are high. The drug candidates are directed
toward indication areas where available therapies are limited or
missing and there are great opportunities to offer significant
improvements to patients. Medivir is focusing on the development of
MIV-818, a pro-drug designed to selectively treat liver cancer
cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's
business model, and the drug development is conducted either by
Medivir or in partnership. Birinapant, a SMAC mimetic, is
exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be
developed in combination with IGM-antibodies for the treatment of
solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq
Stockholm's Small Cap list. www.medivir.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medivir/r/nomination-committee-of-medivir-appointed,c3442902
The following files are available for download:
|
https://mb.cision.com/Main/652/3442902/1488188.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.com/news-releases/nomination-committee-of-medivir-appointed-301411198.html
SOURCE Medivir
